LAWSUITS NEWS & LEGAL INFORMATION
Safyral Legal News Articles & Interviews
Safyral Users May Experience Drospirenone Side Effects
February 1, 2014. By Heidi Turner.
Read [ Safyral Users May Experience Drospirenone Side Effects ]
Baltimore, MD With all the focus on birth control side effects remaining on Yasmin and Yaz, it is easy to forget that Safyral also contains drospirenone and therefore comes with a potential risk of drospirenone side effects. In fact, Safyral is very similar to Yasmin and Yaz, but concerns about Safyral side effects have not been focused on as much as Yasmin and Yaz.
Despite Safyral and Drospirenone Concerns, It’s Business As Usual at Bayer
December 24, 2013. By Gordon Gibb.
Read [ Despite Safyral and Drospirenone Concerns, It’s Business As Usual at Bayer ]
Leverkusen, Germany It’s interesting to note that Bayer’s Third Quarter (Q3) report was released October 31, a date most equate with the observance of Halloween and all things scary. Dressing up is also a hallmark of the Halloween fun, and to that end, there is no shortage of dressing up in any typical corporate report that strives to dispense the required data to shareholders with minimal fuss. Is this why unsavory aspects, including legal implications of drugs such as Safyral, are left to the end?
Safyral: Is There a Link between Drospirenone and Strokes?
November 23, 2013. By Heidi Turner.
Read [ Safyral: Is There a Link between Drospirenone and Strokes? ]
Seattle, WA Strokes in any age group are a cause for concern, but when young women who are relatively healthy suffer a stroke, red flags tend to be raised, particularly when some drugs used primarily by young women have been linked in studies to an increased risk of stroke. This is true of Safyral and other, similar birth control pills. Safyral side effects, according to the US Food and Drug Administration, include an increased risk of blood clots and stroke. Although Safyral is similar to other drugs such as Yasmin and Yaz, it has not received nearly the media attention of those other drugs.
Safyral Expected to Emerge from the Litigation Shadows
October 21, 2013. By Gordon Gibb.
Read [ Safyral Expected to Emerge from the Litigation Shadows ]
Washington, DC As evidenced by the contents of the second-quarter performance summary issued by pharmaceutical giant Bayer, the German manufacturer had settled about 6,760 claims with regard to drospirenone side effects, costing the company about $1.4 billion as of July 8 of this year. Another 5,400 US lawsuits are still pending.
Safyral Is Just Yasmin Beefed Up with Vitamin B
August 21, 2013. By Gordon Gibb.
Read [ Safyral Is Just Yasmin Beefed Up with Vitamin B ]
Falmouth, NS While the Bayer birth control product Safyral lacks the profile of the more talked-about Yasmin and Yaz, any accusation against the latter is a damnation against the former. In other words, there is just as much concern over Safyral blood clots as any of the others. That’s because they all contain drospirenone, which some studies have suggested carries a higher risk for blood clot and deep-vein thrombosis (DVT).
Did Suspected Advisory Panel Bias Affect Safyral et al Vote?
March 29, 2012. By Gordon Gibb.
Read [ Did Suspected Advisory Panel Bias Affect Safyral et al Vote? ]
Washington, DC Given that the new-age contraceptive Safyral contains drospirenone (DRSP) and estradiol (EE), it is not surprising to see that the Bayer-manufactured product was tagged with the same concerns—and label updates—as other products in the Bayer family containing that specific formulation.
FDA Requests Updates to Safyral Label
December 28, 2011. By Heidi Turner.
Read [ FDA Requests Updates to Safyral Label ]
Washington, DC Along with other birth control medications that are caught up in the drospirenone side effects debate is Safyral, a birth control that contains drospirenone and also includes a supplement to help increase levels of folate in women who use the birth control. Concerns about Safyral side effects, brought about because of drospirenone, have resulted in the US Food and Drug Administration (FDA) requesting an update to the contraceptive's label.